¡La cuenta atrás continúa para el gran encuentro de la urología española! ⏳🇪🇸 Del 10 al 12 de junio de 2026, nos vemos en Madrid para celebrar el 89º Congreso Nacional de Urología. Serán tres días para compartir ciencia, innovación, formación, experiencia clínica y mirar hacia el futuro de nuestra especialidad. 📊 El #CNU2026 en cifras será espectacular: 👥 Más de 1.000 participantes 📝 Más de 700 abstracts presentados 🎤 Más de 400 ponentes y moderadores 🏛️ 9 sesiones plenarias 🧪 13 talleres prácticos 🎓 10 cursos de adiestramiento 🤝 **9 sociedades científicas participantes** 💬 Múltiples simposios, debates, vídeos, mesas redondas y actividades paralelas 📍 ¡Nos vemos en Madrid! #CNU2026 #SomosAEU

@FPuigvert comes to #AUA26! 🌍✨ Inspiring discussions, cutting-edge innovations, and valuable connections with colleagues from around the world. Grateful for this experience in a such lovely city #Washington !🚀 @pizquierdog @GAvesaniMD @joanfundi @InfoAeu @EAU_YAUrotheli

🏆🇮🇹 Italian urology shines at #AUA26! The study presented by @danieleamparore during the prestigious Early-Career Investigators Showcase at the American Urological Association Annual Meeting in Washington DC has been awarded the 1st Prize of the session. The presentation focused on AI-enhanced augmented reality for precision robotic prostatectomy, highlighting the growing role of artificial intelligence and advanced imaging integration in robotic urologic surgery. An important international recognition for Italian urological research and for the new generation of investigators driving innovation in our field. Congratulations to Daniele Amparore and the entire Italian team! 🇮🇹👏 #Urology

We validated BCG failure classifications ~5-year progression ≈30% in both BCG-exposed and BCG-unresponsive groups—but salvage RC is used more often in BCG-unresponsive pts doi.org/10.1111/bju.70231 @Pietro9609 @UroMoschini @BenjaminPradere @RobertoContieri @SBoorjian @BJUIjournal

👇🏼Lo que destacamos de nuestra participación en el congreso anual de la European Association of Urology #EAU26 👇🏼 Con la participación de: @oangerri @RodriguezFaba @agallioli @BujonsTur @F_Sanguedolce @joanfundi @DrJM_Gaya @AngeloTerrito @AlbertoBreda1 @koey_kana @Luca_Afferi @lauramasgrillo @a_bravob @ISchwartzmann @LucioF5210 @UroFrancescoDB @CErrandoSmet @pietrosdiana @GAvesaniMD fundacio-puigvert.es/la-fund…

✨ It was such a pleasure to attend #EAU26 this year!
Amazing to see so many innovations and connect with colleagues from around the world. 🌍💡 Coming back with new ideas, research insights, and lots of energy to keep growing! 💪🔬 thankssss🦾 @FPuigvert

3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that it’s in a cisplatin ineligible population (accounting for the poor performance of the control arm). It’s also a smaller trial. The control arm of KN-B15 performed slightly better than NIAGARA (Gem/cis for both), but the trials are otherwise similar. The pCR in the EVP trails and the consistent efficacy of EVP is striking. #GU26

Surgical Technique and Perioperative and Postoperative Outcomes for Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Performed with the Hugo RAS Robotic Platform: First Large Case Series by the European Association of Urology Robotic Urology Section Scientific Working Group sciencedirect.com/science/ar… Multicentre study evaluated robot-assisted radical cystectomy using the Hugo RAS robotic platform in 29 patients undergoing lymph node dissection and intracorporeal urinary diversion. Surgical outcomes demonstrated acceptable operative times, hospital stay, and complication rates comparable to established robotic systems. Despite early adoption, the platform required no procedure-specific modifications, supporting its safety and feasibility and suggesting Hugo RAS represents a viable alternative for complex robotic #BladderCancer surgery. @SimoneScuderi1 @juhana_rautiola @MariaChiaraMCS @francprata @Ruben_De_Groote @EdwLambert @joanfundi @agallioli @BasileG_ @donatocann @UFalagario @GGandaglia @Albert0Briganti @F_Montorsi @RoccoPapaliaUro @oloakr @bernardorocco73 @alexmottrie @_alelarcher @AlbertoBreda1

Continuem amb el Dr Alex Serrallach de @FPuigvert aprofita el seu cas per fer un excel·lent repàs a una patologia infreqüent com és l’extròfia vesical. Enhorabona per la presentació!

So proud for our EAU Endourology Working Group in Lap/focal therapy!! @UroFrancescoDB @barret_e Panagiotis Kallidonis Theodore Tokas @GernotOrtner Tiago Oliveira @GAvesaniMD @AlbertoBreda1 @OTRAXER @Uroweb

More than proud and happy to share that our Stone team @FPuigvert has won two awards during last @InfoAeu EndoUrology Meeting in Murcia #teamworkmakesthedreamwork @koey_kana @a_bravob @paoloverri05 @pizquierdog @LucioF5210

📍Acabem la sessió d’avui amb la Dra @malvessa2 de @FPuigvert qui ens presenta com fer el diagnòstic i el maneig de les masses suprarenals, destacant la importància dels uròlegs en aquesta patologia. Excel·lent presentació!

Congratulations to Prof. Joan Palou Redorta @joanfundi, the first Spanish #urologist to receive the Laurent-Boccon-Gibod Award of the Academic Association of European Urologists (#AAEU) @urowebESU. 🏅This award was delivered this month in Copenhagen in recognition of his contribution to the organisation and development of #Urology in #Europe. #UrologyInEurope #KnowledgeDevelopment

20 years ago we suggested ceasing surveillance in G1Ta #BladderCancer after 5 recurrence-free years: pubmed.ncbi.nlm.nih.gov/1575… From our recent work, further de-intensifiction of surveillance in low risk patients is feasible. authors.elsevier.com/a/1mHug…

Largest comparative study about #RAKT vs #OKT from living donors out today @EurUrolFocus 📊 RARP: ↓ early postop complications & reinterventions ✔️ similar dialysis-free survival, graft survival, OS & renal function 🙏🏻 to all centers involved Link w free access ⬇️

Another study from a rising ⭐️ fellow @Luca_Afferi from @FPuigvert !!

1a intervenció d’un pacient amb hiperplàsia benigna de #pròstata mitjançant #RezumEVO a Espanya, el 2n país on es prova després del Regne Unit. @ISchwartzmann, l’uròleg de la Fundació Puigvert que ha dut a terme la intervenció ahir amb respresentació europea de @BSCEMEA_Urology, l'únic fabricant d'aquesta tecnologia mínimament invasiva pel tractament de la patologia: 🗨️“Ens permet millorar els símptomes miccionals alhora que el pacient conserva l'ejaculació, un efecte col·lateral freqüent dels tractaments estàndard.” Sobre l’experiència d’operar amb el nou dispositiu, afegeix que és “més fàcil de manipular i facilita el treball de l’equip auxiliar i d’infermeria”. 🔘La Fundació ha estat pionera a nivell estatal en l’ús d'aquesta teràpia tèrmica amb vapor d'aigua des dels seus inicis i fa anys que realitza estudis per a millorar els resultats clínics en els pacients. #WVTT #TTVA #urology #urologia #HBP #PBH

A pleasure to be at #ICE25. What a brainstorming congress among the best endourologists from all over the world. I imagined this when I decided to be a researcher/surgeon. @FPuigvert @AlbertoBreda1 @a_bravob @agallioli @koey_kana @BujonsTur @LucioF5210 @oangerri @pedrohpenalver

BN176: Super-successful ICE25 meeting in Rome with more than 1000pax.I really would like to thank all of you for this huge Success.Fantastic Speakers,great 1/2-Live Surgeries,Fabulous EAU team,Incredible support of Companies&Exceptional atmosphere!See you next year ICE26-Valencia

BN172: Newsflash November 2025! D-1 for ICE25 Rome. More than 1000 people registered! ICE25 will be Amazing! Electing the Best Endourologist of the World 2025. 14 semi-Live & top excellence for abstract presentation (15 min each on stage).Because we all LOVE EndoUrology♥️♥️♥️